4
|
Indellicato R, Parini R, Domenighini R, Malagolini N, Iascone M, Gasperini S, Masera N, dall’Olio F, Trinchera M. Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation. Glycobiology 2019; 29:229-241. [DOI: 10.1093/glycob/cwy112] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Revised: 12/14/2018] [Accepted: 12/19/2018] [Indexed: 01/02/2023] Open
Affiliation(s)
- Rossella Indellicato
- Department of Health Sciences, San Paolo Hospital, University of Milan, via A. di Rudinì 8, Milano, Italy
| | - Rossella Parini
- Department of Pediatrics, University Milano Bicocca, Fondazione MBBM, San Gerardo Hospital, via Pergolesi 33, Monza, Italy
- San Raffaele Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute, via Olgettina 60, Milano, Italy
| | - Ruben Domenighini
- Department of Health Sciences, San Paolo Hospital, University of Milan, via A. di Rudinì 8, Milano, Italy
| | - Nadia Malagolini
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, via San Giacomo 14, Bologna, Italy
| | - Maria Iascone
- Laboratory of Genetics, Papa Giovanni XXIII Hospital, Piazza OMS 1, Bergamo, Italy
| | - Serena Gasperini
- Department of Pediatrics, University Milano Bicocca, Fondazione MBBM, San Gerardo Hospital, via Pergolesi 33, Monza, Italy
| | - Nicoletta Masera
- Department of Pediatrics, University Milano Bicocca, Fondazione MBBM, San Gerardo Hospital, via Pergolesi 33, Monza, Italy
| | - Fabio dall’Olio
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, via San Giacomo 14, Bologna, Italy
| | - Marco Trinchera
- Department of Medicine and Surgery (DMC), University of Insubria, via JH Dunant 5, Varese, Italy
| |
Collapse
|
9
|
Jayaraja S, Dakhama A, Yun B, Ghosh M, Lee H, Redente EF, Uhlson CL, Murphy RC, Leslie CC. Cytosolic phospholipase A2 contributes to innate immune defense against Candida albicans lung infection. BMC Immunol 2016; 17:27. [PMID: 27501951 PMCID: PMC4977843 DOI: 10.1186/s12865-016-0165-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 07/25/2016] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The lung is exposed to airborne fungal spores, and fungi that colonize the oral cavity such as Candida albicans, but does not develop disease to opportunistic fungal pathogens unless the immune system is compromised. The Group IVA cytosolic phospholipase A2 (cPLA2α) is activated in response to Candida albicans infection resulting in the release of arachidonic acid for eicosanoid production. Although eicosanoids such as prostaglandins and leukotrienes modulate inflammation and immune responses, the role of cPLA2α and eicosanoids in regulating C. albicans lung infection is not understood. METHODS The responses of cPLA2α(+/+) and cPLA2α(-/-) Balb/c mice to intratracheal instillation of C. albicans were compared. After challenge, we evaluated weight loss, organ fungal burden, and the recruitment of cells and the levels of cytokines and eicosanoids in bronchoalveolar lavage fluid. The ability of macrophages and neutrophils from cPLA2α(+/+) and cPLA2α(-/-) mice to recognize and kill C. albicans was also compared. RESULTS After C. albicans instillation, cPLA2α(+/+) mice recovered a modest weight loss by 48 h and completely cleared fungi from the lung by 12 h with no dissemination to the kidneys. In cPLA2α(-/-) mice, weight loss continued for 72 h, C. albicans was not completely cleared from the lung and disseminated to the kidneys. cPLA2α(-/-) mice exhibited greater signs of inflammation including higher neutrophil influx, and elevated levels of albumin and pro-inflammatory cytokines/chemokines (IL1α, IL1β, TNFα, IL6, CSF2, CXCL1, CCL20) in bronchoalveolar lavage fluid. The amounts of cysteinyl leukotrienes, thromboxane B2 and prostaglandin E2 were significantly lower in bronchoalveolar lavage fluid from C. albicans-infected cPLA2α(-/-) mice compared to cPLA2α(+/+) mice. Alveolar macrophages and neutrophils from uninfected cPLA2α(-/-) mice exhibited less killing of C. albicans in vitro than cells from cPLA2α(+/+) mice. In addition alveolar macrophages from cPLA2α(-/-) mice isolated 6 h after instillation of GFP-C. albicans contained fewer internalized fungi than cPLA2α(+/+) macrophages. CONCLUSIONS The results demonstrate that cPLA2α contributes to immune surveillance and host defense in the lung to prevent infection by the commensal fungus C. albicans and to dampen inflammation.
Collapse
Affiliation(s)
- Sabarirajan Jayaraja
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA
| | - Azzeddine Dakhama
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA
| | - Bogeon Yun
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA
| | - Moumita Ghosh
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA
| | - HeeJung Lee
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA
| | - Elizabeth F Redente
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA
| | - Charis L Uhlson
- Department of Pharmacology, University of Colorado Denver, Aurora, Colorado, USA
| | - Robert C Murphy
- Department of Pharmacology, University of Colorado Denver, Aurora, Colorado, USA
| | - Christina C Leslie
- Department of Pediatrics, National Jewish Health, 1400 Jackson St., Denver, Colorado, 80206, USA. .,Department of Pharmacology, University of Colorado Denver, Aurora, Colorado, USA. .,Department of Pathology, University of Colorado Denver, Aurora, Colorado, USA.
| |
Collapse
|
11
|
Rosengarten M, Hadad N, Solomonov Y, Lamprecht S, Levy R. Cytosolic phospholipase A2 α has a crucial role in the pathogenesis of DSS-induced colitis in mice. Eur J Immunol 2015; 46:400-8. [PMID: 26548451 DOI: 10.1002/eji.201545848] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 09/20/2015] [Accepted: 11/03/2015] [Indexed: 02/06/2023]
Abstract
Colitis, an inflammation of the colon, is a well-characterized massive tissue injury. Cytosolic phospholipase A2 α (cPLA2 α) upregulation plays an important role in the development of several inflammatory diseases. The aim of the present study was to define the role of cPLA2 α upregulation in the development of colitis. We used a mouse model of dextran sulfate sodium induced colitis. Immunoblotting analysis showed that cPLA2 α and NF-κB were upregulated and activated in the colon from day 2 of colitis induction. This molecular event preceded the development of the disease, as determined by Disease Activity Index score, body weight, colon length, and the expression of colonic inflammatory markers, including neutrophil infiltration detected by myeloperoxidase and by NIMP-R14, ICAM-1, COX-2, iNOS upregulation and LTB4 and TNF-α secretion. Prevention of cPLA2 α upregulation and activity in the colon by i.v. administration of specific antisense oligonucleotides against cPLA2 α 1 day prior and every day of exposure to dextran sulfate sodium significantly impeded the development of the disease and prevented NF-κB activation, neutrophils infiltration into the colonic mucosa, and expression of proinflammatory proteins in the colon. Our results demonstrate a critical role of cPLA2 α upregulation in inflammation and development of murine colitis.
Collapse
Affiliation(s)
- Marina Rosengarten
- Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Soroka Medical University Center, Beer-Sheva, Israel
| | - Nurit Hadad
- Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Soroka Medical University Center, Beer-Sheva, Israel
| | - Yulia Solomonov
- Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Soroka Medical University Center, Beer-Sheva, Israel
| | - Sergio Lamprecht
- Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Soroka Medical University Center, Beer-Sheva, Israel
| | - Rachel Levy
- Immunology and Infectious Diseases Laboratory, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Soroka Medical University Center, Beer-Sheva, Israel
| |
Collapse
|
12
|
Kirkby NS, Reed DM, Edin ML, Rauzi F, Mataragka S, Vojnovic I, Bishop-Bailey D, Milne GL, Longhurst H, Zeldin DC, Mitchell JA, Warner TD. Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. FASEB J 2015; 29:4568-78. [PMID: 26183771 PMCID: PMC4608906 DOI: 10.1096/fj.15-275065] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Accepted: 07/06/2015] [Indexed: 12/25/2022]
Abstract
Eicosanoids are important vascular regulators, but the phospholipase A2
(PLA2) isoforms supporting their production within the cardiovascular
system are not fully understood. To address this, we have studied platelets,
endothelial cells, and leukocytes from 2 siblings with a homozygous loss-of-function
mutation in group IVA cytosolic phospholipase A2
(cPLA2α). Chromatography/mass spectrometry was used to determine
levels of a broad range of eicosanoids produced by isolated vascular cells, and in
plasma and urine. Eicosanoid release data were paired with studies of cellular
function. Absence of cPLA2α almost abolished eicosanoid synthesis
in platelets (e.g., thromboxane A2, control 20.5 ±
1.4 ng/ml vs. patient 0.1 ng/ml) and leukocytes
[e.g., prostaglandin E2 (PGE2), control
21.9 ± 7.4 ng/ml vs. patient 1.9 ng/ml], and this was
associated with impaired platelet activation and enhanced inflammatory responses.
cPLA2α-deficient endothelial cells showed reduced, but not
absent, formation of prostaglandin I2 (prostacyclin; control 956 ±
422 pg/ml vs. patient 196 pg/ml) and were primed for inflammation.
In the urine, prostaglandin metabolites were selectively influenced by
cPLA2α deficiency. For example, prostacyclin metabolites were
strongly reduced (18.4% of control) in patients lacking cPLA2α,
whereas PGE2 metabolites (77.8% of control) were similar to healthy
volunteer levels. These studies constitute a definitive account, demonstrating the
fundamental role of cPLA2α to eicosanoid formation and cellular
responses within the human circulation.—Kirkby, N. S., Reed, D. M., Edin, M.
L., Rauzi, F., Mataragka, S., Vojnovic, I., Bishop-Bailey, D., Milne, G. L.,
Longhurst, H., Zeldin, D. C., Mitchell, J. A., Warner, T. D. Inherited human group
IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial,
and leucocyte eicosanoid generation.
Collapse
Affiliation(s)
- Nicholas S Kirkby
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Daniel M Reed
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Matthew L Edin
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Francesca Rauzi
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Stefania Mataragka
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Ivana Vojnovic
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - David Bishop-Bailey
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Ginger L Milne
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Hilary Longhurst
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Darryl C Zeldin
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Jane A Mitchell
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| | - Timothy D Warner
- *National Heart and Lung Institute, Imperial College London, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; Department of Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom; Department of Pharmacology and Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA; and Immunology Department, Barts Health and the London National Health Service Trust, London, United Kingdom
| |
Collapse
|